Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • ROOMS:

Upbeat trial data for GlycoMimetics

GlycoMimetics Inc. (Nasdaq: GLYC) reported upbeat updated data from the Phase 1/2 trial for GMI-1271 to treat relapsed/refractory acute myeloid leukemia. The stock price soared $2.13 to close at $16.45.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.